Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAnnual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, July 7–8, 2015

Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Wolf-Henning Boehncke, Dafna D. Gladman and Philip S. Helliwell
The Journal of Rheumatology May 2016, 43 (5) 949-951; DOI: https://doi.org/10.3899/jrheum.160112
Wolf-Henning Boehncke
From the Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; The University of Toronto; Krembil Research Institute; and the Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; and Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wolf-henning.boehncke@hcuge.ch
Dafna D. Gladman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip S. Helliwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

The 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Stockholm, Sweden, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. In this prologue, we introduce the articles that summarize that meeting. As in previous years, GRAPPA members held a Trainees Symposium, providing an opportunity for trainees to discuss their research in psoriatic disease with experts in the field. Two dermatology sessions were held: an update on the International Dermatology Outcome Measures group; and a description of a new tool, the Comprehensive Assessment of the Psoriasis Patient, to more accurately assess the full burden of plaque psoriasis and its subtypes. Four distinct plenary sessions were held to update members on the status of the Outcome Measures in Rheumatology (OMERACT) initiative. GRAPPA’s patient research partners discussed their 2 years of involvement in GRAPPA activities and were active in several sessions before and during the 2015 annual meeting. New work was presented toward developing a patient-reported instrument to measure flare in psoriatic disease, and the status of GRAPPA’s multiple research and continuing education programs in psoriasis and PsA was summarized. Finally, a Presidential Round Table was held in which the past, current, and incoming presidents reflected on GRAPPA’s history and provided insights about its future.

Key Indexing Terms:
  • PSORIASIS
  • PSORIATIC ARTHRITIS
  • OUTCOME MEASURES
  • OMERACT
  • COMPREHENSIVE ASSESSMENT OF THE PSORIASIS PATIENT
  • FLARE

The 2015 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Stockholm, Sweden, adjacent to the World Psoriasis and Psoriatic Arthritis Congress, and was attended by investigators in rheumatology and dermatology, representatives of biopharmaceutical companies, and patient research partners (PRP, Table 1, Table 2), who discussed individual and collaborative research and education initiatives in psoriasis and psoriatic arthritis (PsA). The goals and list of core projects for GRAPPA, formed in 2003, have been reported (available from: www.grappanetwork.org)1,2,3,4,5,6.

View this table:
  • View inline
  • View popup
Table 1.

Composition of GRAPPA members.

View this table:
  • View inline
  • View popup
Table 2.

GRAPPA executive and steering committee membership.

Prior to the meeting, a trainees symposium was held, providing an opportunity for trainees to discuss their research in psoriatic disease with experts in the field7. In 2015, rheumatology and dermatology researchers from Europe and North and South America who are current members of GRAPPA or who were nominated by GRAPPA members described their studies. Of 26 abstracts that were submitted and ranked by a committee of reviewers led by Christopher T. Ritchlin (Rochester, New York, USA), the 6 top-ranked abstracts were chosen for oral presentation; and 20 additional ones were presented as posters. GRAPPA members provided feedback, including how to improve and further develop the research projects.

On the first day of the annual meeting, Alice Gottlieb (Boston, Massachusetts, USA) led a group that updated GRAPPA members on the 2015 Washington, DC, USA, meeting of the International Dermatology Outcome Measures, a group formed to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy. The 2015 meeting began with a needs assessment review followed by a working meeting around the Delphi process, initially to specifically focus on psoriasis domains in clinical trials and later to include a deeper “dive” into domains for registries and clinical practice8.

Next, a group led by Joseph Merola (Boston, Massachusetts, USA) and Abrar Qureshi (Providence, Rhode Island, USA) introduced the Comprehensive Assessment of the Psoriasis Patient, a novel disease severity measure to more accurately assess the full burden of plaque psoriasis and its subtypes, including inverse, scalp, nail, palmoplantar, and genital psoriasis9.

Ana-Maria Orbai (Baltimore, Maryland, USA), et al led 4 plenary presentations to update GRAPPA members on the status of the Outcome Measures in Rheumatology (OMERACT) initiative: (1) an overview of ongoing projects to achieve patient and clinician consensus on preliminary PsA core sets of domains and outcome measures; (2) a summary of the development of the patient-derived and disease-specific PsA Impact of Disease outcome measure; (3) a presentation of the generic Patient-Reported Outcomes Measurement Information System measures and applicability to PsA; and (4) a patient and clinician focus group project in the United States that identifies how patients and physicians prioritize PsA domains and asks patients about the content validity of PsA outcome measures10.

In an article by Maarten de Wit (Amsterdam, The Netherlands) et al, patient research partners (PRP) discuss their 2 years of involvement in GRAPPA activities11. PRP were active in several sessions before and during the 2015 annual meeting, and held a plenary session entitled, “Let’s Talk About Inclusion,” which included a personal perspective from Willemina Campbell (Toronto, Ontario, Canada) and an opportunity for GRAPPA members to vote on their belief in the benefit of patient involvement in their research.

A group led by Philip S. Helliwell (Leeds, UK) discussed its work toward developing a patient-reported instrument to measure flare in psoriatic disease12. They reported the results from 2 online Delphi surveys of patients and physicians, who attempted to achieve consensus about items that might discriminate disease flare. Eight breakout groups discussed specific aspects of psoriatic disease flares at the annual meeting.

In an article by Philip J. Mease, et al13, the status of GRAPPA’s multiple Internet-based and continuing education programs in psoriasis and PsA were described. Also summarized were updates of the GRAPPA treatment recommendations project, and the development of simple criteria to identify inflammatory musculoskeletal disease; a description of new patient/physician Delphi exercises; the BIODAM project, which identifies biomarkers that predict progressive structural joint damage; and a report from the Publication Committee.

In a special session at the end of the GRAPPA 2015 annual meeting, a Presidential Round Table was held14, in which the past, current, and incoming presidents reflected on GRAPPA’s history and provided insights about its future. Since its inception in 2003, GRAPPA has become a large and productive organization of clinician-researchers, patient service organizations and patient researchers, representatives of biopharmaceutical companies, and others who investigate and care for psoriasis and PsA.

At the conclusion of the GRAPPA meeting, members discussed action items in a business meeting. The next annual meeting will be held in Miami, Florida, USA, in July 2016.

Acknowledgment

Special thanks go to Pam Love for her tireless organizational efforts, which kept the meeting running smoothly; and to Linda Melvin, a meeting organizer who submitted the GRAPPA 2015 articles.

Footnotes

  • Financial support to enable these meetings was provided in 2015 by AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly & Company, Novartis, Pfizer, and UCB. Innovation Partners in 2015 were Covagen, Crescendo, Mallinckrodt, and Sun Pharma.

REFERENCES

  1. 1.↵
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2011;38:522–5.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2012;39:391–3.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Mease PJ,
    2. Gladman DD
    . Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2012;39:2181–3.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Mease PJ,
    2. Boehncke WH,
    3. Gladman DD
    . Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2013;40:1407–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Boehncke WH,
    2. Gladman DD
    . Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2014;41:1194–6.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Boehncke WH,
    2. Gladman DD
    . Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol 2015;42:2011–3.
    OpenUrl
  7. 7.↵
    1. Milliken M,
    2. Generali E,
    3. Marin J,
    4. Ritchlin CT
    . GRAPPA Trainees Symposium 2015: a report from the GRAPPA 2015 Annual Meeting. J Rheumatol 2016;43:952–8.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Merola JF,
    2. Armstrong AW,
    3. Saraiya A,
    4. Latella J,
    5. Garg A,
    6. Callis Duffin K,
    7. et al.
    The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: an update. J Rheumatol 2016;43:959–60.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Paek SY,
    2. Thompson JM,
    3. Qureshi AA,
    4. Merola JF,
    5. Husni ME
    . Comprehensive Assessment of the Psoriasis Patient (CAPP): a report from the GRAPPA 2015 Annual Meeting. J Rheumatol 2016;43:961–4.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Orbai AM,
    2. Mease PJ,
    3. de Wit M,
    4. Kalyoncu U,
    5. Campbell W,
    6. Tillett W,
    7. et al.
    Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. J Rheumatol 2016;43:965–9.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. de Wit M,
    2. Campbell W,
    3. Coates LC,
    4. Gladman DD,
    5. James J,
    6. Lindsay CA,
    7. et al.
    Let’s talk about inclusion: a concise report about patient research partner involvement in the GRAPPA 2015 Annual Meeting. J Rheumatol 2016;43:970–3.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Moverley AR,
    2. Waxman R,
    3. de Wit M,
    4. Parkinson A,
    5. Campbell W,
    6. Brooke M,
    7. et al.
    Development of a flare instrument for use in psoriatic disease: a report from the 2015 GRAPPA Annual Meeting. J Rheumatol 2016;43:974–8.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Mease PJ,
    2. Helliwell PS,
    3. Boehncke WH,
    4. FitzGerald O,
    5. Gladman DD,
    6. Deodhar AA,
    7. et al.
    GRAPPA 2015 research and education project reports. J Rheumatol 2016;43:979–85.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Gladman DD,
    2. Mease PJ,
    3. Boehncke WH,
    4. Helliwell PS,
    5. Callis Duffin K
    . Presidential round table: a report from the GRAPPA Annual Meeting. J Rheumatol 2016;43:986–9.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 43, Issue 5
1 May 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Wolf-Henning Boehncke, Dafna D. Gladman, Philip S. Helliwell
The Journal of Rheumatology May 2016, 43 (5) 949-951; DOI: 10.3899/jrheum.160112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Wolf-Henning Boehncke, Dafna D. Gladman, Philip S. Helliwell
The Journal of Rheumatology May 2016, 43 (5) 949-951; DOI: 10.3899/jrheum.160112
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

PSORIASIS
PSORIATIC ARTHRITIS
OUTCOME MEASURES
OMERACT
COMPREHENSIVE ASSESSMENT OF THE PSORIASIS PATIENT
FLARE

Related Articles

Cited By...

More in this TOC Section

  • International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update
  • Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting
  • Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting
Show more Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, July 7–8, 2015

Similar Articles

Keywords

  • psoriasis
  • psoriatic arthritis
  • outcome measures
  • OMERACT
  • COMPREHENSIVE ASSESSMENT OF THE PSORIASIS PATIENT
  • flare

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire